Clinical Trial Update: PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

This update notes the completion of enrollment for the Phase 2 PEARL-SC trial evaluating A-623 in systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• A 623

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED